Advanced glycation end products market

Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs (Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline) and Fluorescent AGEs (Pentosidine and Methylglyoxal-lysine dimer (MOLD))), by Application (Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, and Others), by End User (Hospitals, Specialty Clinics, and Homecare Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Request Free Sample

Dec 2020
CMI4350
105 Pages
Excel & Pdf
Pharmaceutical

Summary

Advanced glycation end products (AGEs) are a group of compounds, which are formed by non-enzymatic reactions between carbonyl groups of reducing sugars and free amino groups of proteins, lipids or nucleic acids and can be obtained exogenously from diet or formed endogenously within the body. AGEs accumulate intracellularly and extracellularly in all tissues and body fluids and can cross-link with other proteins and thus affect their normal functions.

The global advanced glycation end products market is estimated to be valued at US$ 1,368.5 million in 2020 and is expected to exhibit a CAGR of 6.3% over the forecast period (2020-2027).

Figure 1. Global Advanced Glycation End Products Market Share (%), By Region, 2019

Increasing cases of cancer is expected to propel the market growth over the forecast period

The increasing number of cancer cases worldwide is expected to boost the market growth, as AGEs significantly increase the level of inflammation in the body which has long been associated with the development of cancer. For instance, according to the National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024 in the U.S.

Similarly, according to the American Cancer Society, 2015, an estimated 4.3 million new cancer cases and over 2.8 million cancer deaths were recorded in China, with lung cancer being the most common and the leading cause of cancer death.

Advanced Glycation End Products Market Report Coverage

Report Coverage	Details
Base Year:	2019	Market Size in 2020:	US$ 1,368.5 Mn
Historical Data for:	2016 to 2019	Forecast Period:	2020 to 2027
Forecast Period 2020 to 2027 CAGR:	6.3%	2027 Value Projection:	US$ 2,130.1 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Non-fluorescent AGEs, Fluorescent AGEs. By Application: Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, Others. By End User: Hospitals, Specialty Clinics, Homecare Settings.
Companies covered:	Allergan Plc, Estée Lauder Companies, Shiseido Company, Beiersdorf AG, L'Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc, Alma Laser, and Rodan & Fields, LLC
Growth Drivers:	Increasing product approvals and launches Increasing number of aesthetic procedures Increasing collaborations, acquisitions, and partnerships
Restraints & Challenges:	High cost of aesthetic procedures

Figure 2. Global Advanced Glycation End Products Market Share (%), by Type, 2020

Increasing cases of neurodegenerative diseases is expected to drive the market growth over the forecast period

Increasing cases of neurodegenerative diseases such as Alzheimer’s, Parkinson’s diseases, and other are expected to drive the market growth over the forecast period, as AGEs are proteins and glycated after exposure to sugars that is contribute to the development of neurodegenerative diseases. For instance, according to the World Alzheimer Report 2015 published by Alzheimer’s Disease International (ADI), in 2015 the new dementia cases in the regions were 4.9 million (49.0%) in Asia, 2.5 million (25.0%) in Europe, 1.7 million (18.0%) in the Americas, and 0.8 million (8.0%) in Africa. Furthermore, according to the Parkinson's UK, in 2015 there were around 137,000 people suffered from Parkinson’s in the U.K.

Global Advanced Glycation End Products Market – Impact of Coronavirus (Covid-19) Pandemic

Advanced glycation products (AGEs) resulting from the fixing of sugars on proteins, create cross links which definitively reduce the elasticity of elastin used in the aesthetic procedures. The American Society of Plastic Surgeons has recommended to postpone all the elective or non-essential services due to which the number of aesthetic procedures such as chemical peel, botulinum toxin therapy, dermabrasion, and others have decreased hindering the advanced glycation end products market growth. According to the article published in the Aesthetic Journal on April 03, 2020, around 81% of clinics are closed and 67% are experiencing reduction in revenue due to the COVID-19 lockdown in London.

Furthermore, several skincare and cosmetic companies are observing a decline in sales due to the COVID-19 pandemic. For instance, on May 12, 2020, Shiseido Company, a Japan-based multinational personal care company, released its financial statement for the first quarter of 2020 reporting a 14.6% and 19.2% year-on-year net sales decline in the American and Asia Pacific business, respectively.

Advanced Glycation End Products Market Restraint

High cost of aesthetic procedures is expected to hinder the market growth over the forecast period. According to the American Society of Plastic Surgeons, the average cost of botox treatment is US$ 397 in the U.S. while a single session of microdermabrasion costs around US$ 131 and the cost of chemical peel is around US$ 669.

Key Players

Major players operating in the global advanced glycation end products market include Allergan Plc, Estée Lauder Companies, Shiseido Company, Beiersdorf AG, L'Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc, Alma Laser, Rodan & Fields, LLC, and others.

Table of Content

*Browse 25 market data tables and 20 figures on “Advanced Glycation End Products Market” - Global forecast to 2027

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

The global advanced glycation end products market size is estimated to be valued at US$ 21.06 billion in 2019 and is expected to exhibit a CAGR of 7.3% between 2020 and 2027.

What are the major factors driving the Advanced Glycation End Products market growth?

The increasing launches of advanced glycation end products, increasing number of chronic diseases, research and development in advanced glycation end products by major players, and increasing geriatric population are driving the Advanced Glycation End Products market growth.

Which is the leading type segment for the demand of Advanced Glycation End Products market?

Non-fluorescent AGEs segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.

Which region holds the largest market share in the Advanced Glycation End Products market?

North America advanced glycation end products market is expected to generate highest revenue share during the forecast period.

What are the key factors hampering growth of the market?

Major factors hampering growth of the market include high cost of cosmetic procedures.

Which are the major players operating in the market?

Major players operating in the global advanced glycation end products market include Merck KGaA, Diagnoptics Technologies B.V., Cell Biolabs, Inc., Shanghai Korain Biotech Co., Ltd, Scent-Sations, Inc., Z.I. de la Nau, and KOKEN CO., LTD. among others. .